Navigation Links
Velos to Develop Key System Interface for Clinical Research
Date:3/26/2008

- Will facilitate tight integration between sponsors and investigators -

FREMONT, Calif., March 26 /PRNewswire/ -- Velos, Inc., a recognized leader and trusted resource for clinical trial management information systems and member of the Oracle PartnerNetwork, will work to develop a key interface between Velos eResearch and Oracle Clinical. Both software products serve to advance clinical research. Velos eResearch is widely installed at research sites, while Oracle Clinical holds a leadership position among research sponsors.

When complete, Oracle Clinical customers should be able to populate Velos eResearch with content, such as research protocols, case reports and data dictionaries, which will then be used by Velos sites for study fulfillment. Velos eResearch customers should then be able to return study information collected through eResearch to Oracle Clinical where it can be integrated and analyzed together with information collected from other sources. This two-way system handshake will help to ensure consistency, greatly reduce redundant data entry and foster other systematic efficiencies that will enable higher quality, more timely clinical research fulfillment for sponsors and investigators alike.

"Oracle Clinical customers have expressed the desire to interoperate with systems used at research sites," said Neil de Crescenzo, Group Vice President, Healthcare and Life Sciences, Oracle. "Velos is a clear leader among clinical trial management systems used at research sites in the U.S., particularly among larger academic medical centers. We welcome their plan to develop an interface between Velos eResearch and Oracle Clinical."

Velos eResearch is deployed by 21 top 25 academic medical centers and research institutions named in the U.S. News & World Report, 2007 Best Hospitals Survey. In the same survey, 14 of the 18 institutions receiving "Honor Roll" status are Velos customers. Approximately 30 percent of all NIH (National Institutes of Health) and 35 percent of all NCI (National Cancer Institute) extramural grants go to Velos customers. 12 of the current 24 CTSA (Clinical and Translational Science Award) winners are also Velos customers.

"Oracle has a huge footprint and leadership position in the life sciences, CRO, and medical device industries," said John McIlwain, President and CEO of Velos, Inc. "We're very pleased to be working to implement a robust system handshake between Velos eResearch and Oracle Clinical. We expect the interface will be a great benefit to many Velos customers and their research sponsors."

Traditional EDC (electronic data capture) requires investigators and their staff to leave behind their in-house systems, login to the sponsor's system, enter trial data, and return again to whatever systems and devices they use on a day-to-day basis. While this is an improvement over paper-based methods for sponsors, clinical research fulfillment in its current automated form is still an incomplete system supply chain as a result of work redundancies at the site that are, in effect, reinforced, by the current system model.

"The current state-of-the-art in EDC can actually increase the workloads for many research sites," explained McIlwain. "This in turn adversely impacts sponsor productivity and contributes to the extended time periods required to conduct clinical trials and obtain related drug/device approvals. We look forward to addressing these intrinsic supply chain barriers."

"From an economic perspective, particularly for sponsors," continued McIlwain, "significant advantages result from improved clinical trial timeliness that an integrated supply chain model creates. These gains in turn translate to better treatment options sooner for patients. The technology is there, we just need to put the system handshakes in place."

About the Oracle PartnerNetwork

Oracle PartnerNetwork is a global business network of more than 19,500 companies who deliver innovative software solutions based on Oracle software. Through access to Oracle's premier products, education, technical services, marketing and sales support, the Oracle PartnerNetwork program provides partners with the resources they need to be successful in today's global economy. Oracle partners are able to offer their customers leading-edge solutions backed by Oracle's position as the world's largest enterprise software company. Partners who are able to demonstrate superior product knowledge, technical expertise and a commitment to doing business with Oracle qualify for the Certified Partner levels. http://oraclepartnernetwork.oracle.com

About Velos

Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to participate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eTools, a companion product to Velos eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third party data submissions. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit http://www.velos.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

Trademarks

Oracle is a registered trademark of Oracle Corporation and/or its affiliates.


'/>"/>
SOURCE Velos, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
2. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
3. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
7. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
8. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
9. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
10. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
11. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, ... in repurposing drugs to treat rare nervous system diseases, has ... clinically develop and market the drug SOM0226 against transthyretin amyloidosis ... achieved very promising results in a Phase 2 study conducted ... new office in the United States ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it ... the market opens on Thursday, July 27, 2017. ... a teleconference on Thursday, July 27, 2017, at 9:00 ... 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... ... The Los Angeles leg of the US movie premier of the Man in the Camo ... the Clive Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the ... Welsh rock musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer ...
(Date:7/27/2017)... ... 27, 2017 , ... Cremations recently surpassed traditional burials for the first time ... expected to continue with over 70% of Americans projected to choose cremation by 2030. ... that enable families to celebrate the life of a lost loved one in different ...
(Date:7/26/2017)... ... ... greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the American ... blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives have ... have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood drives ...
(Date:7/26/2017)... Maryland (PRWEB) , ... July ... ... Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation ... These concurrent events offer comprehensive solutions to process validation lifecycle challenges faced ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
Breaking Medicine News(10 mins):